Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
duvelisib · 1 trial · 1 indication
The number of participants reporting treatment-emergent adverse events.
| Arm | Type | Description |
|---|---|---|
| duvelisib | EXPERIMENTAL | Duvelisib will be administered orally as a fixed dose in 28-day cycles. |
| Name | Type | Description |
|---|---|---|
| duvelisib | DRUG | Duvelisib will be administered orally as a fixed dose in 28-day cycles. |
Inclusion Criteria: * Diagnosis of lymphoma (excluding lymphoblastic lymphoma) * Progressed during, refractory to, intolerant of, or ineligible for established therapy, or has a disease for which there is no established therapy * Eastern Cooperative Oncology Group (ECOG) performance status lower th...
Top 20 of 66 competitors
Duvelisib is an investigational small molecule being studied for the treatment of lymphoma. It is being evaluated in patients with relapsed or refractory lymphoma, meaning the cancer has returned or has not responded to prior treatment. The drug is currently in Phase 1 clinical development for this indication.
Duvelisib is being developed by AbbVie Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol ABBV. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with lymphoma.
Duvelisib is in Phase 1 clinical development for the treatment of lymphoma. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still undergoing clinical trials to assess its safety and effectiveness in patients.
Duvelisib has been studied in a Phase 1 clinical trial with the identifier NCT02598570. This trial evaluated the drug in Japanese subjects with relapsed or refractory lymphoma. The study has been completed and enrolled a total of 7 participants.
Duvelisib is not FDA approved. It is an investigational drug currently in Phase 1 clinical development for the treatment of lymphoma. The drug has not completed the clinical trial process necessary to obtain regulatory approval, and its safety and efficacy have not been fully established.